Proxy Votes Now

Home › Funds › Equitable › EQ/T. Rowe Price Health Sciences Portfolio

EQ/T. Rowe Price Health Sciences Portfolio proxy voting record 2025-2026

Fund family: Equitable · Filed by EQ ADVISORS TRUST (CIK 1027263) · SEC series S000062644

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,345 with, 27 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Equitable as a whole

The same two figures as Equitable’s manager page (393,894 ballot items across 72 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsEquitableItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.4%1,28092.5%339,726
Backed environmental and social shareholder proposals at US companiesn/a89.6%3,486

Where this fund voted differently from most Equitable funds

Each ballot item this fund voted is set against the votes of the other Equitable funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Equitable funds on 55 items (5.2% of the 1,061 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Equitable fundsMgmtResult
AbbVie Inc.2026-05-08Election of Class II Directors: Frederick H. WaddellAgainstFOR — 21 of 21 Equitable fundsAgainstPassed (calculated), 93.7% support
AbbVie Inc.2026-05-08Election of Class II Directors: Jennifer L. DavisAgainstFOR — 21 of 21 Equitable fundsAgainstPassed (calculated), 93.1% support
AbbVie Inc.2026-05-08Election of Class II Directors: Melody B. MeyerAgainstFOR — 21 of 21 Equitable fundsAgainstPassed (calculated), 98.3% support
Waters Corporation2026-01-27To approve the adjournment of the Special Meeting, if necessary, (a) to solicit additional proxies in the event there are not sufficient votes at the time of the Special Meeting to approve the Share Issuance Proposal, (b) if there are insufficient shares of Waters Common Stock represented (either inAgainstFOR — 22 of 22 Equitable fundsAgainst—
IQVIA Holdings Inc.2026-04-23Approve the adoption of the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan.AgainstFOR — 20 of 21 Equitable fundsAgainstApproved, 65.5% support
Denali Therapeutics Inc.2026-06-03ELECTION OF DIRECTORS: Jennifer CookForWITHHOLD — 9 of 9 Equitable fundsForElected, 60.9% support
Chugai Pharmaceutical Co., Ltd.2026-03-26Elect Director Okuda, OsamuAgainstFOR — 9 of 9 Equitable fundsAgainst—
Mirum Pharmaceuticals, Inc.2026-06-15To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy WalbertForWITHHOLD — 8 of 8 Equitable fundsForElected, 69.7% support
Scholar Rock Holding Corporation2026-06-04To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kristina BurowForWITHHOLD — 8 of 8 Equitable fundsForElected, 81.6% support
Scholar Rock Holding Corporation2026-06-04To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Michael GilmanForWITHHOLD — 8 of 8 Equitable fundsForElected, 78.2% support
Xenon Pharmaceuticals Inc.2026-06-02To approve the Corporation's 2026 Equity Incentive Plan;AgainstFOR — 8 of 8 Equitable fundsAgainstApproved, 68.0% support
Palvella Therapeutics, Inc.2026-06-10Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5.AgainstFOR — 8 of 8 Equitable fundsAgainstPassed (calculated), 75.2% support
Stoke Therapeutics, Inc.2026-06-03Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Adrian Krainer, Ph.D.ForWITHHOLD — 8 of 8 Equitable fundsForPassed (calculated), 73.0% support
Ionis Pharmaceuticals, Inc.2026-06-04Election of Directors: Joan E. HermanAgainstFOR — 7 of 7 Equitable fundsAgainstPassed (calculated), 96.4% support
Corvus Pharmaceuticals, Inc.2026-06-11To elect two Class I Directors with terms to expire at the 2029 annual meeting of stockholders: Linda S. Grais, M.D. J.D.ForWITHHOLD — 7 of 7 Equitable fundsForPassed (calculated), 87.2% support
Wave Life Sciences Ltd.2025-08-05The election of the nominees for director: Christian HenryForAGAINST — 7 of 7 Equitable fundsForPassed (calculated), 85.4% support
Rocket Pharmaceuticals, Inc.2026-05-20The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Peter Fong, Ph.D.WithholdFOR — 7 of 7 Equitable fundsAgainstPassed (calculated), 98.1% support
Apogee Therapeutics, Inc.2026-06-09Election of Class III Directors for terms expiring in 2029: William (BJ) Jones, Jr.ForWITHHOLD — 7 of 7 Equitable fundsForPassed (calculated), 81.5% support
MBX Biosciences, Inc.2026-06-04Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersForWITHHOLD — 6 of 6 Equitable fundsForPassed (calculated), 80.8% support
Agios Pharmaceuticals, Inc.2026-06-18To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia SmithForWITHHOLD — 6 of 6 Equitable fundsForPassed (calculated), 68.3% support
Alumis Inc.2026-06-30To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: Zhengbin (Bing) Yao, Ph.D.ForWITHHOLD — 6 of 6 Equitable fundsForPassed (calculated), 84.1% support
Evommune, Inc.2026-06-02To elect two nominees for Class I directors, each to hold office until the 2029 Annual Meeting of Stockholders: Luis PenaWithholdFOR — 6 of 6 Equitable fundsAgainst—
Iovance Biotherapeutics, Inc.2026-06-10To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.AgainstFOR — 5 of 5 Equitable fundsAgainst—
Caris Life Sciences, Inc.2026-06-04Election of Directors: Peter M. CastlemanForWITHHOLD — 8 of 9 Equitable fundsForElected, 76.3% support
Moderna, Inc.2026-05-06To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: SaForAGAINST — 13 of 17 Equitable fundsForElected, 81.0% support
Show all 55
Items 26 to 55.
CompanyMeetingItemThis fundMost Equitable fundsMgmtResult
Inspire Medical Systems, Inc.2026-04-30Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal No. 5 and/or Proposal No. 6.AgainstFOR — 4 of 4 Equitable fundsAgainstApproved, 94.4% support
Boston Scientific Corporation2026-04-30Shareholder Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting."AgainstFOR — 14 of 20 Equitable fundsForNot approved, 42.8% support
Thermo Fisher Scientific Inc.2026-05-20An advisory vote to approve named executive officer compensation.ForAGAINST — 11 of 16 Equitable fundsForNot approved, 31.8% support
UroGen Pharma Ltd.2025-08-26To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D.ForWITHHOLD — 5 of 6 Equitable fundsForElected, 91.0% support
Celcuity Inc.2026-05-14Elect eight directors: Polly A. MurphyWithholdFOR — 5 of 7 Equitable fundsAgainstPassed (calculated), 91.1% support
Celcuity Inc.2026-05-14Elect eight directors: Richard E. BullerWithholdFOR — 5 of 7 Equitable fundsAgainstPassed (calculated), 90.3% support
Repligen Corporation2026-05-14Election of Directors: Glenn P. MuirForAGAINST — 7 of 11 Equitable fundsForElected, 74.4% support
Caris Life Sciences, Inc.2026-06-04Election of Directors: Danny PhillipsForWITHHOLD — 6 of 9 Equitable fundsForElected, 81.8% support
Caris Life Sciences, Inc.2026-06-04Election of Directors: Laura I. JohansenForWITHHOLD — 6 of 9 Equitable fundsForElected, 86.5% support
Rhythm Pharmaceuticals, Inc.2026-06-24Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David W.J. McGirrForWITHHOLD — 5 of 8 Equitable fundsForPassed (calculated), 85.9% support
Iovance Biotherapeutics, Inc.2026-06-10To approve, by non-binding advisory vote, the compensation of our named executive officers;AgainstFOR — 3 of 4 Equitable fundsAgainst—
Celcuity Inc.2026-05-14To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan.ForAGAINST — 4 of 6 Equitable fundsFor—
Inspire Medical Systems, Inc.2026-04-30Approval of an amendment and restatement of the Inspire Medical Systems, Inc. 2018 Incentive Award Plan.AgainstFOR — 3 of 4 Equitable fundsAgainstApproved, 62.0% support
Ultragenyx Pharmaceutical Inc.2026-05-14Nominees: Daniel G. WelchForWITHHOLD — 3 of 4 Equitable fundsForPassed (calculated), 90.1% support
Ultragenyx Pharmaceutical Inc.2026-05-14Nominees: Shehnaaz Suliman, M.D.ForWITHHOLD — 3 of 4 Equitable fundsForPassed (calculated), 89.4% support
Rocket Pharmaceuticals, Inc.2026-05-20The approval of the proposed stock option exchange program; andAgainstFOR — 4 of 6 Equitable fundsAgainstApproved, 72.1% support
Rocket Pharmaceuticals, Inc.2026-05-20The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. SouthwellWithholdFOR — 4 of 6 Equitable fundsAgainstPassed (calculated), 68.2% support
Kestra Medical Technologies, Ltd.2025-09-03The approval of the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan.ForAGAINST — 4 of 6 Equitable fundsFor—
Cytokinetics, Incorporated2026-05-273 wordings Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.WithholdFOR — 5 of 9 Equitable fundsAgainstPassed (calculated), 97.0% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith ManchesterForWITHHOLD — 4 of 7 Equitable fundsForElected, 70.6% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa EpperlyForWITHHOLD — 4 of 7 Equitable fundsForElected, 73.5% support
Guardant Health, Inc.2026-06-17Election of Class II Directors: Ian ClarkForWITHHOLD — 4 of 7 Equitable fundsForElected, 65.0% support
Guardant Health, Inc.2026-06-17Election of Class II Directors: Manuel Hidalgo MedinaForWITHHOLD — 4 of 7 Equitable fundsForElected, 75.5% support
BioMarin Pharmaceutical Inc.2026-06-02Election of Directors: Ian T. ClarkForAGAINST — 4 of 7 Equitable fundsForElected, 88.3% support
Mirum Pharmaceuticals, Inc.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Lon Cardon, Ph.D., FMedSciForWITHHOLD — 4 of 7 Equitable fundsForElected, 85.3% support
Mirum Pharmaceuticals, Inc.2026-06-15To elect the Board's three Class I nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: William FaireyForWITHHOLD — 4 of 7 Equitable fundsForElected, 86.8% support
Alignment Healthcare, Inc.2026-06-04Election of Directors: David HodgsonWithholdFOR — 3 of 5 Equitable fundsAgainstElected, 60.8% support
Alignment Healthcare, Inc.2026-06-04Election of Directors: Jacqueline KosecoffWithholdFOR — 3 of 5 Equitable fundsAgainstElected, 76.1% support
Alignment Healthcare, Inc.2026-06-04Election of Directors: Jody BilneyWithholdFOR — 3 of 5 Equitable fundsAgainstElected, 76.1% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Mostafa RonaghiForWITHHOLD — 2 of 3 Equitable fundsForPassed (calculated), 99.9% support

Download all 55 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 77.5% of this fund’s 1,372 such votes could be given a sector; the other 309 (22.5%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care997232.3%
Industrials4924.1%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections8070
Audit-related1590
Say-on-Pay1400
Compensation1072
Capital Structure840
Corporate Governance7416
Other Social Issues75
Shareholder Rights and Defenses71
Extraordinary Transactions40
Environment or Climate33

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Eli Lilly and CompanyMay 4, 2026$28M102
Thermo Fisher Scientific Inc.May 20, 2026$9M130
argenx SENovember 18, 2025$9M10
UnitedHealth Group IncorporatedJune 1, 2026$8M121
Merck & Co., Inc.May 26, 2026$7M183
AbbVie Inc.May 8, 2026$6M81
argenx SEMay 6, 2026$6M120
Intuitive Surgical, Inc.April 30, 2026$6M130

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
June 1, 2026UnitedHealth Group IncorporatedIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
May 14, 2026CVS Health CorporationStockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposalAgainstFor
May 13, 2026Elevance Health, Inc.Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposalAgainstFor

Search this fund’s votes by company

1,392 ballot items at 160 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, EQ/T. Rowe Price Health Sciences Portfolio voted at 160 shareholder meetings of 156 companies, on 1,392 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 27 times. Its most frequent area of disagreement was corporate governance (16 of its votes against management). It voted on 26 shareholder proposals. It voted FOR the board's own proposals about as often as Equitable's funds as a whole (92.4% against 92.5%). It voted differently from most Equitable funds on 55 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Equitable’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.